The Incidental Resolution of Severe Alcohol Use Disorder during Esketamine Treatment of Major Depressive Disorder: A Case Report
Open Access
- 15 December 2022
- journal article
- case report
- Published by Wiley in Case Reports in Psychiatry
- Vol. 2022, 1-4
Abstract
Alcohol use disorder (AUD) is especially prevalent among individuals with major depressive disorder (MDD) and is associated with higher morbidity, mortality, disability, and risk for suicide. Intranasal esketamine has been documented to be a safe and effective option for treatment resistant MDD and received US FDA approval in 2019. However, the availability of esketamine is limited due to requirements for a Risk Evaluation and Mitigation Strategy program for its administration as well as concerns over substance use disorders (SUD) as a potential contraindication or adverse effect. This case presents a 61-year-old female with a history of severe recurrent treatment resistant MDD and severe AUD who has expressed interest in esketamine. To date, she has completed 20 sessions of 56 mg intranasal esketamine twice a week before increasing to 5 weekly sessions and then 14 weekly sessions of 84 mg. Although there was immediate subjective improvement in mood as well as reductions in PHQ-9 and HAM-D scores, the dosage was increased to extend the therapeutic benefit throughout the entire intertreatment interval. She was able to complete these sessions without complication. Incidentally, she also reported decreased desire to use alcohol, decreased impulsivity, and the complete cessation of alcohol use by the second week. While on 56 mg, she had a single relapse of binging which was addressed with motivational therapy and has remained alcohol-free since. This case presents the first documented example of the safe and effective use of intranasal esketamine in patient with treatment resistant MDD in which there was incidental resolution of their comorbid severe AUD. This suggests that esketamine can be used without risk of SUD onset or exacerbation. Thus, esketamine should not be discounted in patients with SUD and continued research is needed to further elucidate its role in treating SUD.Keywords
This publication has 18 references indexed in Scilit:
- The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-AnalysisAmerican Journal of Psychiatry, 2018
- Ketamine for Depression, 3: Does Chirality Matter?The Journal of Clinical Psychiatry, 2017
- Party drug’s power to fight depression puzzles scientistsNature, 2017
- Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled StudyBiological Psychiatry, 2016
- NMDAR inhibition-independent antidepressant actions of ketamine metabolitesNature, 2016
- Differences Among Major Depressive Disorder With and Without Co-occurring Substance Use Disorders and Substance-Induced Depressive DisorderThe Journal of Clinical Psychiatry, 2012
- Measuring Depression at the End of LifeAssessment, 2008
- The impact of comorbid anxiety and depression on alcohol treatment outcomesAddiction, 2005
- The prevalence and impact of alcohol problems in major depression: A systematic reviewThe American Journal of Medicine, 2005
- The PHQ-9Journal of General Internal Medicine, 2001